Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 1 · 50%High 0 · 0%

Adverse events (52–60 weeks) · people with Crohn's disease

Vedolizumab showed no clear difference in adverse events (52–60 weeks) compared with placebo (moderate certainty).

1 finding from 1 review

Vedolizumab for induction and maintenance of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 1 [0.94, 1.07]
3 studies · 894 participants
Moderate

Serious adverse events (52–60 weeks) · people with Crohn's disease

Vedolizumab showed no clear difference in serious adverse events (52–60 weeks) compared with placebo (low certainty).

1 finding from 1 review

Vedolizumab for induction and maintenance of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 0.98 [0.68, 1.39]
3 studies · 894 participants
Low